Moreover, owing to the heterogeneity of the tumor microenvironment, the proposed combination strategies might only be effective in HCC with high CXCL2 expression, indicating the potential of CXCL2 as a predictive biomarker for patient stratification. This evidence concerns the gene CXCL2 and hepatocellular carcinoma.